Corcept Therapeutics Stock Plunges As Court Clears Teva Generic
Corcept Therapeutics Inc (NASDAQ:CORT) shares are under heavy pressure Thursday morning after the U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey district court decision finding no infringement of two Korlym-related patents by Teva Pharmaceutical Industries Ltd’s (NASDAQ:TEVA) proposed generic.
- Corcept Therapeutics shares are approaching critical lows. What’s pressuring CORT?
Appeals Court Upholds Ruling Against Corcept
Corcept had argued that Teva's label for its generic version of Korlym, a drug used to treat Cushing's syndrome, would induce doctors to follow patented dosing methods involving mifepristone and strong CYP3A inhibitors such as ketoconazole.
The appeals court agreed with the lower court that there was no proof doctors had used, or were likely to use, those specific regimens, especially given safety concerns and the availability of newer alternatives like osilodrostat.
Generic Threat Clouds Korlym Outlook For CORT
The ruling removes a major legal barrier for Teva's Korlym generic, increasing the risk of earlier-than-hoped competition to Corcept's flagship franchise once regulatory requirements are satisfied.
With the court concluding that Teva's label can be followed without practicing Corcept's claimed methods, the company loses a key patent shield around Korlym's dosing with CYP3A inhibitors.
For investors, the decision heightens uncertainty around the durability of Korlym revenue and puts more pressure on Corcept to diversify its portfolio and demonstrate growth from pipeline programs as potential generic erosion looms.
Shares Sink Below Key Averages
Corcept is currently trading 24.4% below its 20-day simple moving average (SMA) and 52.9% below its 100-day SMA, indicating a significant bearish trend.
Over the past 12 months, shares have decreased by 57.55%, and they are positioned closer to their 52-week lows than highs, suggesting ongoing weakness in the stock.
Earnings Report Due Feb. 24
The countdown is on: Corcept Therapeutics Inc. is set to report earnings on Feb. 24.
- EPS Estimate: 31 cents (Up from 26 cents)
- Revenue Estimate: $254.72 million (Up from $181.89 million)
- Valuation: P/E of 36x (Indicates premium valuation)
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $100.00. Recent analyst moves include:
- Canaccord Genuity: Buy (Raises Target to $100.00) (Jan. 23)
- HC Wainwright & Co.: Buy (Raises Target to $105.00) (Jan. 23)
- Canaccord Genuity: Buy (Lowers Target to $99.00) (Jan. 2)
CORT Shares Fall Sharply Thursday
CORT Price Action: Corcept Therapeutics shares were down 19.79% at $31.95 at the time of publication on Thursday. The stock is trading at a new 52-week low.
Image: Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Before the Jensen Huang scandal broke out, the Quant King precisely cleared out Nvidia!
The latest 13F filing shows that quantitative giant Renaissance Technologies almost completely sold off its holdings in Nvidia (reduced by 99.7%), Meta (reduced by 99.9%), as well as other tech giants like Apple and Amazon in the third quarter, and significantly reduced its position in Palantir. At the same time, it heavily increased its holdings in Micron Technology (up by 618.7%), AMD, and SanDisk, as well as other storage and chip stocks.
British Pound extends losing streak against US Dollar, US PPI in focus
Barclays: US-Iran conflict unlikely to end in next 12 months, oil exports near 85% of pre-war level
Jensen Huang's sudden resignation shrouded in suspicion: Did the White House secretly intervene? Is a return possible in the future?
Only a few days separated Jensen Huang’s strong support from the board last Sunday and his late-night resignation on Wednesday. Multiple reports of the Wednesday night Nvidia board meeting were co-authored by Washington-based journalists—who do not typically cover Nvidia—fueling rumors of "White House pressure and information leaks." Huang’s unique value lies in leveraging his personal reputation to secure the supply chain and drive the implementation of technological roadmaps, making him difficult to replace. Some analysts note that, drawing on examples such as Steve Jobs’ return to Apple, it is possible that Huang may come back in the future.
Crypto prices
More
